| Recruiting | 3 | 232 | Europe, US, RoW | Polyhexamethylene biguanide (PHMB), Polyhexanide, Topical corticosteroid, Topical placebo | Jeremy Keenan, MD, MPH, Johns Hopkins University, Oregon Health and Science University, University of Illinois at Chicago, University of Michigan, University of California, Los Angeles, University of Pittsburgh, University of Pennsylvania, Columbia University, University of Iowa, University of Florida, Aravind Eye Care System, Moorfields Eye Hospital NHS Foundation Trust, Federal University of São Paulo, National Eye Institute (NEI) | Acanthamoeba Keratitis | 07/28 | 07/28 | | |
EXPEDE, NCT04081103: NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries |
|
|
| Terminated | 2 | 35 | US | Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Placebo, Open-label Nexagon® (lufepirsen) | Amber Ophthalmics, Inc. | Corneal Persistent Epithelial Defect | 02/22 | 02/22 | | |
| Not yet recruiting | 2 | 96 | US | Corneal Donor Tissue with Cross Linking, Treatment, Corneal Donor Tissue without Cross Linking, Control | Massachusetts Eye and Ear Infirmary | Corneal Transplant Failure | 01/28 | 01/31 | | |
| Active, not recruiting | N/A | 40 | US | Cenegermin Ophthalmic Solution [Oxervate] | University of California, Los Angeles, Dompé Farmaceutici S.p.A | Neurotrophic Keratitis | 02/25 | 02/25 | | |
